美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

减肥药

1,479.65

-12.5227-0.84%

涨家数：3

跌家数：4

平家数：- -

市盈率：- -

高：1,485.06

开：1,483.83

低：1,470.83

收：1,492.17

数据加载中...

总览新闻资讯

一次宇宙级合作

礼来推出高剂量小瓶减肥药，价格比注射笔低 150 美元

诺和诺德美股盘前续涨近4%

每日经济新闻

辉瑞任命前FDA药物主管为新任首席医疗官兼执行副总裁

辉瑞(PFE.US)达成临床开发合作评估双抗新药联合治疗多种实体瘤效果

在研药物 “数据欺诈”风波：诺和诺德向KBP索赔8.3亿美元

中国经营报

速递｜被诺和诺德索赔60亿元，KBP Biosciences涉嫌“造假”

GLP1减重宝典

前 FDA 药品中心主任加入辉瑞，担任首席医疗官

Insight数据库

礼来首次披露新型减重药个案数据来凯医药(02105)已成中国ActRII靶点“领军者”

华泰证券：全球GLP-1产品空缺较大，并购潮有望持续

【美国FDA前官员Cavazzoni将重返辉瑞，出任首席医疗官】辉瑞当地时间2月24日宣布，Patrizia Cavazzoni将出任公司首席医疗官，接替将离职寻求其他机会的Aida Habtezion。Cavazzoni最近的职务是美国食品药品监督管理局（FDA）药物评估与研究中心主任，于今年1月辞职。在此之前，Cavazzoni曾在辉瑞担任过多个高级职位，负责临床科学与开发业务。

GLP-1研发风云录：MetaBio折戟沉沙，辉瑞缘何错失良机？

BUZZ-Summit Therapeutics 因第四季度亏损扩大和投资者对交易的预期而下跌

硕迪生物盘中异动急速下挫5.20%

【欧股“十一罗汉”｜诺和诺德收涨超1.4%，阿斯麦涨约0.5%】周一，阿斯麦控股荷兰阿姆斯特丹股价收涨0.48%，报713.50欧元。诺和诺德哥本哈根股价收涨1.46%，报639.20。雀巢收涨3.15%，葛兰素史克涨1.65%，阿斯利康、欧莱雅、诺华、德国思爱普Sap涨0.55%-0.26%。罗氏制药和赛诺菲则至多收跌0.71%，LVMH集团跌1.47%。此外，欧洲芯片概念股普跌，BE半导体实业收跌2.17%，英飞凌、意法半导体至多跌1.29%，德国爱思强则涨1.76%。

辉瑞任命前 FDA 总监 Patrizia Cavazzoni 为首席医疗官

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK4599/news?page=5"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4599"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","market":"US","secType":"PLATE","nameCN":"减肥药","latestPrice":1479.6505,"timestamp":1741277925050,"preClose":1492.1732,"halted":0,"volume":15339237,"delay":0,"changeRate":-0.008392,"change":-12.522705,"pbRate":11.780703,"amount":1557445354.748522,"amplitude":0.00954,"prevYearClose":1305.0607,"fiveDayClose":1460.4895,"twentyDayClose":1394.0055,"turnoverRate":0.001453,"marketCap":1591493724608,"floatMarketCap":1477955345632,"peRate":41.703544},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","high":1485.0612,"amplitude":0.00954,"preClose":1492.1732,"low":1470.8256,"pbRate":"11.780703","latestPrice":1479.6501,"volume":15339394,"delay":0,"open":1483.8325,"prevYearClose":1305.0607,"prevWeekClose":1482.1702,"prevMonthClose":1482.1702,"prevQuarterClose":1305.0607,"fiveDayClose":1460.4895,"twentyDayClose":1394.0055,"sixtyDayClose":1438.0239,"secType":"PLATE","market":"US","turnoverRate":0.001453,"peRate":41.703544,"marketCap":1591522898880,"floatMarketCap":1477984433952,"timestamp":1741277926730,"nameCN":"减肥药"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4599\",,,,undefined,":{"bkCode":"BK4599","up":3,"down":4,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4599\",pageSize:16,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514072060","title":"一次宇宙级合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2514072060","media":"瞪羚社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514072060?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 20:05","pubTimestamp":1740485100,"startTime":"0","endTime":"0","summary":"01辉瑞目前的困境众所周知，宇宙药厂辉瑞在新冠期间靠疫苗和特效药发了横财，并且在2024年，它都是制药业务板块营收最高的MNC。排名第一的是派柏西利，治疗乳腺癌的CDK4/6抑制剂，小分子爆款单品的代表，排名第二的是恩杂鲁胺，治疗前列腺癌的抗雄激素受体小分子。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226124834abdd4ad3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226124834abdd4ad3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BJT1NW94.SGD","BK4139","SGXZ57979304.SGD","LU2089984988.USD","LU0058720904.USD","LU0225284248.USD","IE00BJJMRZ35.SGD","LU1291159041.SGD","LU1023059063.AUD","LU0170899867.USD","LU0203347892.USD","LU2468319806.SGD","BK4568","LU0320765489.SGD","LU0266013472.USD","LU1066053197.SGD","LU2023250843.SGD","LU0070302665.USD","LU1934455863.HKD","IE00BFTCPJ56.SGD","LU1093756325.SGD","LU2361044949.HKD","BK4599","SG9999002224.SGD","LU1037948897.HKD","BK4550","LU0208291251.USD","LU1116320901.HKD","LU1934455277.USD","LU1983299246.USD","IE00BSNM7G36.USD","LU1894683264.USD","SMMT","BK4588","LU2106854487.HKD","BK4592","SG9999001176.SGD","PFE","MRK","SG9999014575.USD","LU2361045086.USD","LU1585245621.USD","LU1162221912.USD","SG9999013999.USD","SG9999001176.USD","LU0211331839.USD","LU0456855351.SGD","LU0006306889.USD","LU1989772840.SGD","LU0238689110.USD"],"gpt_icon":0},{"id":"2514060602","title":"礼来推出高剂量小瓶减肥药，价格比注射笔低 150 美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514060602","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514060602?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 19:45","pubTimestamp":1740483904,"startTime":"0","endTime":"0","summary":"路透社2月25日 - 礼来LLY.N周二表示，该公司已开始在美国销售高剂量的流行减肥药Zepbound小瓶装，价格比注射笔版本便宜150美元，以刺激对该药的进一步需求。这比礼来公司向有保险但不在药品范围内的患者收取的 650 美元自动注射器费用低了近 23%。本周二，该公司表示已将这些剂量的一个月用量的价格分别下调了约50美元。礼来公司表示，患者必须在首次配药后 45 天内重新配药，才能获得相同的价格，否则重复配药的费用将高达 699 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nL3S3PG10F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1035775433.USD","SG9999015952.SGD","LU1280957306.USD","LU0203202063.USD","LU0061475181.USD","LU1548497426.USD","LU0882574139.USD","LU1623119135.USD","IE00BJLML261.HKD","LU1917777945.USD","LU2461242641.AUD","LU1720051017.SGD","LU2491050154.USD","LU0289739699.SGD","SG9999013999.USD","LU0640476718.USD","IE00B1BXHZ80.USD","LU1291159041.SGD","LU2112291526.USD","LU2237438978.USD","LU0354030511.USD","LU1868836914.USD","LU1814569148.SGD","LU2468319806.SGD","LU0256863902.USD","LU0417517546.SGD","SG9999014880.SGD","SGXZ51526630.SGD","LU1069344957.HKD","LU2237443549.SGD","LU1127390331.HKD","LU2237443382.USD","LU0689472784.USD","LU0708995401.HKD","LU2361044865.SGD","SG9999018857.SGD","LU0820561909.HKD","LU0471298777.SGD","LLY","SG9999014906.USD","SGXZ31699556.SGD","LU1712237335.SGD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU2063271972.USD","LU1804176565.USD","LU1023059063.AUD","BK4599","LU1974910355.USD","BK4533"],"gpt_icon":1},{"id":"2514706691","title":"诺和诺德美股盘前续涨近4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514706691","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514706691?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 17:34","pubTimestamp":1740476068,"startTime":"0","endTime":"0","summary":"诺和诺德美股盘前续涨近4%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202502253329082570.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502253329082570.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BKVL7J92.USD","NVO","BK4599","BK4007","LU1093756325.SGD","BK4585","BK4588","LU0154236417.USD","IE00BZ1G4Q59.USD","BK4532","LU1093756168.USD"],"gpt_icon":0},{"id":"2514055452","title":"辉瑞任命前FDA药物主管为新任首席医疗官兼执行副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2514055452","media":"医药魔方","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514055452?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 15:11","pubTimestamp":1740467475,"startTime":"0","endTime":"0","summary":"2月24日，辉瑞宣布，前FDA药物主管Patrizia Cavazzoni将重新加入辉瑞，担任首席医疗官兼执行副总裁，领导辉瑞的监管、药物警戒、安全、流行病学、医疗信息和证据生成等医疗职能，并向辉瑞研发首席科学官兼总裁Chris Boshoff博士汇报。2019年，Cavazzoni加入FDA，担任代理首席副主任专员，并于2021年被任命为CDER的正式主任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225151629abdbf956&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225151629abdbf956&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4533","LU0234572021.USD","LU0306806265.USD","LU1066051498.USD","IE00BLSP4452.SGD","LU0122379950.USD","SG9999002232.USD","SG9999011175.SGD","SGXZ57979304.SGD","LU1066053197.SGD","IE00BBT3K403.USD","LU0170899867.USD","LU0289739699.SGD","LU0321505439.SGD","BK4585","SG9999003800.SGD","BK4592","BK4550","BK4599","LU0985481810.HKD","LU1894683264.USD","LU1883839398.USD","SG9999002224.SGD","IE000M9KFDE8.USD","IE00B19Z3B42.SGD","LU0306807586.USD","LU0058720904.USD","IE0002270589.USD","LU1057294990.SGD","SG9999013999.USD","LU1894683348.USD","SG9999001176.USD","IE00BLSP4239.USD","LU0225284248.USD","BK4581","PFE","BK4534","BK4007","BK4588","IE00B19Z3581.USD","SG9999001176.SGD","BK4568","LU0321505868.SGD","LU0868494617.USD","LU1023059063.AUD","LU0456855351.SGD","LU0225771236.USD"],"gpt_icon":1},{"id":"2514030461","title":"辉瑞(PFE.US)达成临床开发合作 评估双抗新药联合治疗多种实体瘤效果","url":"https://stock-news.laohu8.com/highlight/detail?id=2514030461","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514030461?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 14:29","pubTimestamp":1740464999,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Summit Therapeutics公司今天宣布，与辉瑞开展临床试验合作，评估在研靶向PD-1/VEGF的双特异性抗体ivonescimab，与辉瑞的多种抗体偶联药物联用，治疗多种实体瘤的效果。康方生物公开资料指出，鉴于VEGF和PD-1在肿瘤微环境中的共表达，与联合疗法相比，该产品作为单一药物同时阻断这两个靶点，可能会更有效地阻断这两个信号通路，增强抗肿瘤活性。此外，与联合疗法相比，ivonescimab安全性优势显著，与VEGF靶点相关的毒副作用大幅度降低。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253912.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0321505439.SGD","LU1057294990.SGD","LU0058720904.USD","IE00B19Z3581.USD","LU1066051498.USD","IE0002270589.USD","LU1066053197.SGD","SG9999013999.USD","BK4007","LU1894683264.USD","SG9999003800.SGD","LU0456855351.SGD","BK4585","BK4599","LU0225284248.USD","BK4581","SGXZ57979304.SGD","LU0306806265.USD","BK4550","IE00B19Z3B42.SGD","LU0170899867.USD","BK4533","IE00BBT3K403.USD","SG9999002224.SGD","SG9999001176.SGD","LU0321505868.SGD","LU0868494617.USD","LU0122379950.USD","LU0289739699.SGD","LU1894683348.USD","PFE","SG9999011175.SGD","BK4592","IE00BLSP4239.USD","LU0985481810.HKD","IE00BLSP4452.SGD","LU0225771236.USD","LU0306807586.USD","LU1883839398.USD","LU0234572021.USD","SG9999002232.USD","IE000M9KFDE8.USD","LU1023059063.AUD","SG9999001176.USD","BK4568","BK4534","BK4588"],"gpt_icon":1},{"id":"2514031598","title":"在研药物 “数据欺诈”风波：诺和诺德向KBP索赔8.3亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514031598","media":"中国经营报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514031598?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 12:39","pubTimestamp":1740458345,"startTime":"0","endTime":"0","summary":"近期，全球制药巨头诺和诺德（NovoNordisk）向新加坡生物技术公司KBPBiosciences（中文名：亨利医药，以下简称“KBP”）及其创始人黄振华提起高达8.3亿美元的索赔诉讼，指控后者在药物交易中存在欺诈行为。资料显示，KBP由黄振华于2011年在中国山东济南创立，后在新加坡注册成立全球总部，并在美国费城设立分部。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502253328830375.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0154236417.USD","LU1093756168.USD","LU1093756325.SGD","IE00BZ1G4Q59.USD","BK4588","BK4599","NVO","BK4532","IE00BKVL7J92.USD","BK4585","BK4007"],"gpt_icon":1},{"id":"2514526057","title":"速递｜被诺和诺德索赔60亿元，KBP Biosciences涉嫌“造假”","url":"https://stock-news.laohu8.com/highlight/detail?id=2514526057","media":"GLP1减重宝典","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514526057?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 11:30","pubTimestamp":1740454232,"startTime":"0","endTime":"0","summary":"整理 | GLP1减重宝典内容团队早在 2023 年，诺和诺德就承诺向 KBP Biosciences支付高达 13 亿美元购买一种高血压和肾病药物，当时认为有潜力成为同类最佳。在这种药物去年年底惨败后，诺和诺德现在将责任归咎于该药物的原制造商涉嫌欺诈而索赔。此前，诺和诺德已向新加坡法院提出请求，要求全球冻结 KBP 和黄振华的资产，法官批准了这一请求。诺和诺德于 2023 年 10 月以高达 13 亿美元的价格收购了ocedurenone。KBP Biosciences是一家处于临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225161229abdc1018&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225161229abdc1018&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","BK4532","IE00BZ1G4Q59.USD","LU0154236417.USD","LU1093756325.SGD","BK4599","LU1093756168.USD","IE00BKVL7J92.USD","BK4007","NVO"],"gpt_icon":0},{"id":"2514051917","title":"前 FDA 药品中心主任加入辉瑞，担任首席医疗官","url":"https://stock-news.laohu8.com/highlight/detail?id=2514051917","media":"Insight数据库","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514051917?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 11:08","pubTimestamp":1740452908,"startTime":"0","endTime":"0","summary":"当地时间 2 月 24 日，根据外媒 Endpoint News 新闻，美国 FDA 前药品审评与研究中心主任 Patrizia Cavazzoni 将成为辉瑞新任首席医疗官，负责“监管、药物警戒、安全、流行病学以及医疗信息和证据生成”，直接向首席科学官 Chris Boshoff 汇报。加入 FDA 之前，Patrizia Cavazzoni 曾在制药行业工作多年。值得注意的是，前 FDA 局长 Scott Gottlieb 目前是辉瑞董事会成员。本月，FDA 设备和放射健康中心、烟草产品中心  和 CDER 多个部门又发生大规模裁员。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225155631abdc092f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225155631abdc092f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0321505439.SGD","LU1057294990.SGD","LU0058720904.USD","IE00B19Z3581.USD","LU1066051498.USD","IE0002270589.USD","LU1066053197.SGD","SG9999013999.USD","BK4007","LU1894683264.USD","SG9999003800.SGD","LU0456855351.SGD","BK4585","BK4599","LU0225284248.USD","BK4581","SGXZ57979304.SGD","LU0306806265.USD","BK4550","IE00B19Z3B42.SGD","LU0170899867.USD","BK4533","IE00BBT3K403.USD","SG9999002224.SGD","SG9999001176.SGD","LU0321505868.SGD","LU0868494617.USD","LU0122379950.USD","LU0289739699.SGD","LU1894683348.USD","PFE","SG9999011175.SGD","BK4592","IE00BLSP4239.USD","LU0985481810.HKD","IE00BLSP4452.SGD","LU0225771236.USD","LU0306807586.USD","LU1883839398.USD","LU0234572021.USD","SG9999002232.USD","IE000M9KFDE8.USD","LU1023059063.AUD","SG9999001176.USD","BK4568","BK4534","BK4588"],"gpt_icon":1},{"id":"2514085237","title":"礼来首次披露新型减重药个案数据 来凯医药(02105)已成中国ActRII靶点“领军者”","url":"https://stock-news.laohu8.com/highlight/detail?id=2514085237","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514085237?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 08:38","pubTimestamp":1740443915,"startTime":"0","endTime":"0","summary":"2024年6月，来凯医药的LAE102针对超重/肥胖适应症，在中国开展的I期临床试验就已经启动，并完成了首例受试者给药。来凯医药在ActRIIA靶点的快速进展，甚至引起了手握Bimagrumab的全球巨头礼来的关注。根据双方的协议，礼来将负责在美国执行一项I期临床研究并承担相关费用，而来凯医药则保留LAE102的全球权利。同时，来凯医药在ActRII靶点已经完成了全面的布局：靶向ActRIIA的抗体LAE102以及靶向ActRIIB的抗体LAE103，以及对标Bimagrumab、同时靶向ActRIIA/IIB的双靶点抗体LAE123。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253777.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2361044949.HKD","LU1064131342.USD","LU1035775433.USD","SG9999015952.SGD","LU2237443622.USD","SG9999001176.USD","LU1280957306.USD","LU1623119135.USD","LU0061475181.USD","IE00BJLML261.HKD","LU2264538146.SGD","LU2602419157.SGD","SG9999014898.SGD","LU0943347566.SGD","LU0672654240.SGD","BK4581","SG9999013999.USD","LU0640476718.USD","LU1291159041.SGD","LU0354030438.USD","LU0354030511.USD","LU1868836914.USD","LU0820561818.USD","LU1868837300.USD","IE0009355771.USD","LU0256863902.USD","LU0417517546.SGD","SG9999014880.SGD","LU1989771016.USD","LU1720051108.HKD","LU2324357040.USD","LU2237443549.SGD","LU2361044865.SGD","LU0079474960.USD","LU1988902786.USD","LU1267930730.SGD","LLY","LU2106854487.HKD","SG9999014914.USD","SGXZ31699556.SGD","BK4588","LU0097036916.USD","LU2237443978.SGD","SG9999015978.USD","02105","LU1023059063.AUD","LU2237443465.HKD","LU2491049909.HKD","BK4599","LU1057294990.SGD"],"gpt_icon":1},{"id":"2514083586","title":"华泰证券：全球GLP-1产品空缺较大，并购潮有望持续","url":"https://stock-news.laohu8.com/highlight/detail?id=2514083586","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514083586?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 08:18","pubTimestamp":1740442696,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["SG9999014914.USD","LU1814569148.SGD","LU0354030511.USD","LU0689472784.USD","LU2361044865.SGD","LU1868837300.USD","NVO","LU0943347566.SGD","BK4590","LU0198837287.USD","LU0238689110.USD","LU0882574139.USD","BK4599","LU1035775433.USD","SGXZ81514606.USD","HTSC.UK","LU2361045086.USD","LU1623119135.USD","LU0820561909.HKD","06886","LU2491050154.USD","GLP","SG9999014898.SGD","IE00BJJMRZ35.SGD","SG9999018865.SGD","LU1988902786.USD","LU2264538146.SGD","LU2265009873.SGD","LU0672654240.SGD","LU2063271972.USD","LLY","SG9999015986.USD","LU1720051017.SGD","LU2361044949.HKD","LU0097036916.USD","SG9999001176.SGD","LU0471298694.HKD","IE00B2B36J28.USD","SG9999015978.USD","BK1147","LU0154236417.USD","BK1564","LU2360106947.USD","LU0203202063.USD","LU1804176565.USD","LU2148510915.USD","LU1064131342.USD","601688","LU0006306889.USD","BK4532"],"gpt_icon":0},{"id":"2514088626","title":"【美国FDA前官员Cavazzoni将重返辉瑞，出任首席医疗官】辉瑞当地时间2月24日宣布，Patrizia Cavazzoni将出任公司首席医疗官，接替将离职寻求其他机会的Aida Habtezion。Cavazzoni最近的职务是美国食品药品监督管理局（FDA）药物评估与研究中心主任，于今年1月辞职。在此之前，Cavazzoni曾在辉瑞担任过多个高级职位，负责临床科学与开发业务。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514088626","media":"金融界","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514088626?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 07:47","pubTimestamp":1740440856,"startTime":"0","endTime":"0","summary":"辉瑞当地时间2月24日宣布，Patrizia Cavazzoni将出任公司首席医疗官，接替将离职寻求其他机会的Aida Habtezion。Cavazzoni最近的职务是美国食品药品监督管理局（FDA）药物评估与研究中心主任，于今年1月辞职。在此之前，Cavazzoni曾在辉瑞担任过多个高级职位，负责临床科学与开发业务。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/25074748359132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SG9999011175.SGD","LU0868494617.USD","LU0306806265.USD","SG9999001176.USD","LU0985481810.HKD","LU1066053197.SGD","SG9999002232.USD","IE00B19Z3581.USD","LU1894683348.USD","LU0289739699.SGD","BK4581","SG9999003800.SGD","SG9999013999.USD","SGXZ57979304.SGD","IE00BBT3K403.USD","LU0225771236.USD","BK4585","159891","LU0456855351.SGD","LU1883839398.USD","BK4568","LU0306807586.USD","PFE","LU0058720904.USD","SG9999001176.SGD","BK4007","IE000M9KFDE8.USD","LU1066051498.USD","LU0321505439.SGD","LU0225284248.USD","SG9999002224.SGD","LU0321505868.SGD","BK4588","BK4592","IE00BLSP4452.SGD","LU0170899867.USD","LU0122379950.USD","LU0234572021.USD","LU1894683264.USD","IE0002270589.USD","IE00B19Z3B42.SGD","LU1023059063.AUD","IE00BLSP4239.USD","BK4599","BK4550","BK4534","LU1057294990.SGD","BK4533"],"gpt_icon":0},{"id":"2514088406","title":"GLP-1研发风云录：MetaBio折戟沉沙，辉瑞缘何错失良机？","url":"https://stock-news.laohu8.com/highlight/detail?id=2514088406","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514088406?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 07:30","pubTimestamp":1740439838,"startTime":"0","endTime":"0","summary":"一个月后，MetaBio获得了GLP-1用于糖尿病疗法的全球独家许可。正式合作法律文件于1988年7月签署，MetaBio/辉瑞合作研发正式启动。2辉瑞退出GLP-1合作开发MetaBio/辉瑞联盟由一个联合研究委员会监督，辉瑞任命全球研发高级副总裁和中央研究院研发运营总监负责该项目，辉瑞参与者的资历表明了他们兴趣的强烈程度。辉瑞表示，将确定开发除注射以外的GLP-1给药途径，例如经鼻或经皮。当时MetaBio团队和创始人强烈反对辉瑞的观点。之后诺和诺德获得了哈贝纳的GLP-1专利权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225074833a25287d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225074833a25287d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4550","LU0456855351.SGD","BK4007","BK4533","LU0985481810.HKD","LU1894683348.USD","SG9999011175.SGD","IE00BLSP4452.SGD","LU1057294990.SGD","IE00B19Z3B42.SGD","LU0225771236.USD","PFE","IE0002270589.USD","LU0170899867.USD","LU0321505439.SGD","LU1883839398.USD","BK4599","SG9999003800.SGD","LU0289739699.SGD","LU1066051498.USD","LU0058720904.USD","LU1023059063.AUD","BK4581","SG9999001176.SGD","LU1066053197.SGD","IE00B19Z3581.USD","IE00BBT3K403.USD","SGXZ57979304.SGD","LU0234572021.USD","BK4534","SG9999001176.USD","BK4144","LU0306806265.USD","SG9999002232.USD","LU0225284248.USD","LU0868494617.USD","LU0306807586.USD","LU0122379950.USD","SG9999013999.USD","SG9999002224.SGD","LU0321505868.SGD","GLP","BK4568","BK4590","BK4585","BK4588","LU1894683264.USD","IE00BLSP4239.USD","IE000M9KFDE8.USD","BK4592"],"gpt_icon":1},{"id":"2514770591","title":"BUZZ-Summit Therapeutics 因第四季度亏损扩大和投资者对交易的预期而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2514770591","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514770591?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 03:23","pubTimestamp":1740425029,"startTime":"0","endTime":"0","summary":"2月24日 -  ** 药物开发商Summit Therapeutics SMMT.O股价下跌12.6%至19.33美元 ** 公司公布第四季度净亏损为6110万美元，分析师预计为亏损6054万美元。** 券商 Truist Securities 分析师表示：\"据我们从买方讨论中了解到的情况，他们对交易公告抱有一定的期望，或许比 SMMT 与辉瑞之间披露的交易更具经济性。** 券商补充说：\"我们认为，SMMT 参与投资者会议的变化可能不是潜在交易公告的良好指标\"。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nL3T3PF1CZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0321505439.SGD","BK4139","LU0058720904.USD","LU1057294990.SGD","IE00B19Z3581.USD","LU1066051498.USD","IE0002270589.USD","LU1066053197.SGD","SG9999013999.USD","BK4007","LU1894683264.USD","SG9999003800.SGD","LU0456855351.SGD","BK4585","BK4599","SMMT","LU0225284248.USD","BK4581","SGXZ57979304.SGD","LU0306806265.USD","BK4550","IE00B19Z3B42.SGD","LU0170899867.USD","BK4533","IE00BBT3K403.USD","SG9999002224.SGD","SG9999001176.SGD","LU0321505868.SGD","LU0868494617.USD","LU0122379950.USD","LU0289739699.SGD","LU1894683348.USD","SG9999011175.SGD","BK4592","IE00BLSP4239.USD","LU0985481810.HKD","IE00BLSP4452.SGD","LU0225771236.USD","LU0306807586.USD","LU1883839398.USD","LU0234572021.USD","SG9999002232.USD","IE000M9KFDE8.USD","LU1023059063.AUD","SG9999001176.USD","BK4568","BK4534","LU2488822045.USD","BK4588"],"gpt_icon":1},{"id":"2514677231","title":"硕迪生物盘中异动 急速下挫5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514677231","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514677231?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 02:15","pubTimestamp":1740420914,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日02时15分，硕迪生物股票出现异动，股价大幅下跌5.20%。截至发稿，该股报22.53美元/股，成交量18.0791万股，换手率0.32%，振幅5.09%。机构评级方面，在所有11家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体跌幅为0.37%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225021514abdb3f53&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225021514abdb3f53&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GPCR","BK4007","BK4599"],"gpt_icon":0},{"id":"2514666774","title":"【欧股“十一罗汉”｜诺和诺德收涨超1.4%，阿斯麦涨约0.5%】周一，阿斯麦控股荷兰阿姆斯特丹股价收涨0.48%，报713.50欧元。诺和诺德哥本哈根股价收涨1.46%，报639.20。雀巢收涨3.15%，葛兰素史克涨1.65%，阿斯利康、欧莱雅、诺华、德国思爱普Sap涨0.55%-0.26%。罗氏制药和赛诺菲则至多收跌0.71%，LVMH集团跌1.47%。此外，欧洲芯片概念股普跌，BE半导体实业收跌2.17%，英飞凌、意法半导体至多跌1.29%，德国爱思强则涨1.76%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514666774","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514666774?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 01:50","pubTimestamp":1740419418,"startTime":"0","endTime":"0","summary":"周一，阿斯麦控股荷兰阿姆斯特丹股价收涨0.48%，报713.50欧元。诺和诺德哥本哈根股价收涨1.46%，报639.20。雀巢收涨3.15%，葛兰素史克涨1.65%，阿斯利康、欧莱雅、诺华、德国思爱普Sap涨0.55%-0.26%。罗氏制药和赛诺菲则至多收跌0.71%，LVMH集团跌1.47%。此外，欧洲芯片概念股普跌，BE半导体实业收跌2.17%，英飞凌、意法半导体至多跌1.29%，德国爱思强则涨1.76%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/25015048358625.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["STM","IE0004445239.USD","BK4182","ASML","LU0097036916.USD","LU2506951792.HKD","159813","LU0211331839.USD","NVS","BK4585","IE00B2B36J28.USD","BE","LU2236285917.USD","IE00BJJMRZ35.SGD","BK4541","LRLCY","LU2294711713.HKD","BK4141","BK4007","IE00BJT1NW94.SGD","NSRGY","LU1642822529.SGD","BK4605","LU2063271972.USD","BK4568","BK4147","GSK","BK4554","LU1093756325.SGD","LU1815336760.USD","LU2417539215.USD","LU0109394709.USD","IE00BZ1G4Q59.USD","LU0444973449.USD","IE00BMPRXN33.USD","LU1829250122.USD","IE00BD6J9T35.USD","BK4578","AZN","BK4212","IE00BFTCPJ56.SGD","01477","GSK.UK","LU1093756168.USD","BK4599","NVO","03165","159582","LU0823434583.USD","LU0823434740.USD"],"gpt_icon":0},{"id":"2514755647","title":"辉瑞任命前 FDA 总监 Patrizia Cavazzoni 为首席医疗官","url":"https://stock-news.laohu8.com/highlight/detail?id=2514755647","media":"路透中文","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514755647?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 00:13","pubTimestamp":1740413621,"startTime":"0","endTime":"0","summary":"辉瑞任命前 FDA 总监 Patrizia Cavazzoni 为首席医疗官路透社2月24日 - 辉瑞PFE.N周一表示，美国食品及药物管理局药物中心前负责人帕特里齐亚-卡瓦佐尼将加入该公司，担任首席医疗官。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nL3T3PF182:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","IE0002270589.USD","LU1023059063.AUD","IE00BLSP4452.SGD","IE00BBT3K403.USD","BK4534","LU0122379950.USD","LU1894683264.USD","BK4592","IE00BLSP4239.USD","BK4588","LU1894683348.USD","LU0289739699.SGD","LU0868494617.USD","LU1066053197.SGD","SG9999013999.USD","LU1057294990.SGD","SG9999002224.SGD","SG9999011175.SGD","LU0321505439.SGD","SG9999001176.SGD","BK4007","IE00B19Z3581.USD","LU0306806265.USD","LU1066051498.USD","LU0321505868.SGD","BK4585","LU1883839398.USD","LU0170899867.USD","LU0306807586.USD","LU0225284248.USD","SG9999002232.USD","BK4581","IE00B19Z3B42.SGD","SG9999003800.SGD","IE000M9KFDE8.USD","BK4568","LU0058720904.USD","SGXZ57979304.SGD","SG9999001176.USD","LU0225771236.USD","LU0456855351.SGD","PFE","BK4533","BK4599","LU0985481810.HKD","LU0234572021.USD"],"gpt_icon":0}],"pageSize":16,"totalPage":7,"pageCount":5,"totalSize":110}]}}